Berger S L, Scagliotti R H, Lund E M
Sacramento Animal Medical Group, Carmichael, California 95608, USA.
J Am Anim Hosp Assoc. 1995 May-Jun;31(3):236-41. doi: 10.5326/15473317-31-3-236.
The effect of trimethoprim-sulfadiazinea on Schirmer tear test (STT) values was studied in a population of dogs treated with the drug for a variety of medical and postsurgical conditions. The objectives of the study were to determine the incidence of keratoconjunctivitis sicca (KCS) secondary to trimethoprim-sulfadiazine therapy; to determine if such incidence was related to dose, duration, or both; and to identify any other factors that increased patient risk. The package insert accompanying Tribrissen states that "Dogs can tolerate up to ten times the recommended therapeutic dose without exhibiting ill effects." The results of this study indicated a 15.2% (5/33) incidence of KCS in the population of treated dogs.
在一群因各种内科和外科术后疾病而接受甲氧苄啶 - 磺胺嘧啶治疗的犬中，研究了该药物对泪液分泌试验（STT）值的影响。该研究的目的是确定甲氧苄啶 - 磺胺嘧啶治疗继发的干眼症（KCS）的发生率；确定这种发生率是否与剂量、疗程或两者都有关；并确定任何其他增加患病风险的因素。Tribrissen的药品说明书指出：“犬能耐受高达推荐治疗剂量十倍的剂量而无不良反应。” 本研究结果表明，在接受治疗的犬群中，干眼症的发生率为15.2%（5/33）。
